FDA Accepts For Review AstraZeneca's Supplemental Biologics License Application For Self-Administration Of FluMist Quadrivalent
Portfolio Pulse from Charles Gross
The US FDA has accepted AstraZeneca's supplemental Biologics License Application (sBLA) for review. The application is for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray flu vaccine. If approved, FluMist will be the first self-administered flu vaccine. The FDA's decision is expected in Q1 2024.
October 24, 2023 | 8:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's sBLA for a self-administered option of FluMist has been accepted for review by the FDA. If approved, it could potentially increase the company's market share in the flu vaccine market.
The acceptance of the sBLA by the FDA is a positive step for AstraZeneca. If approved, the self-administered FluMist could potentially increase the company's market share in the flu vaccine market by providing a unique and convenient option for patients. This could lead to increased revenues for the company, positively impacting the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100